Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma.

Blood advances·2026
Same author

Axes of biological variation in diffuse large B cell lymphoma.

Cancer cell·2026
Same author

Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphoma.

British journal of haematology·2025
Same author

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies.

Blood neoplasia·2025
Same author

The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas.

British journal of haematology·2025

Related Experiment Video

Updated: Jul 19, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Drug resistance in diffuse large B-cell lymphoma.

Wyndham H Wilson1

  • 1Center for Cancer Treatment, National Cancer Institute, Bethesda, MD.

Seminars in Hematology
|October 10, 2006
PubMed
Summary

Drug resistance in diffuse large B-cell lymphoma (DLBCL) hinders treatment success. Understanding molecular pathways and incorporating molecular endpoints in trials are crucial for overcoming resistance and improving patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) treatment faces challenges due to drug resistance, a significant cause of therapeutic failure.
  • Early treatment strategies were largely unsuccessful, lacking a deep understanding of resistance mechanisms.
  • Advances in molecular pharmacology and tumor biology have improved therapeutic approaches.

Purpose of the Study:

  • To review the complexities of drug resistance in DLBCL.
  • To highlight the role of molecular profiling in understanding DLBCL biology and resistance.
  • To discuss novel therapeutic targets and the need for molecular endpoints in clinical trials.

Main Methods:

  • Review of current literature on DLBCL drug resistance.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Related Experiment Videos

Last Updated: Jul 19, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

  • Analysis of insights from microarray profiling and molecular taxonomy.
  • Examination of emerging drug targets and clinical trial designs.

    • Main Results:

    • Drug resistance in DLBCL is a complex, dynamic process influenced by cell cycle, apoptosis, differentiation, and the microenvironment.
    • Molecular profiling has elucidated DLBCL subtypes and lymphomagenesis pathways, informing resistance mechanisms.
    • Targeted therapies against pathways like NF-kappaB, CDKs, and BCL-2 are under investigation.

    Conclusions:

    • Understanding the molecular basis of DLBCL drug resistance is essential for developing effective treatments.
    • Future clinical trials must integrate molecular translational endpoints to identify resistance mechanisms and guide therapy.
    • Targeting specific molecular pathways offers promise for overcoming drug resistance in DLBCL.